Resunab Significantly Decreased Fibrotic Response and Exerted Potent Anti-Fibrotic Effects in Bleomycin-Induced Lung Fibrosis When Administered During Early and Later Stages of Fibrogenesis; Poster Presentation Today, April 1, 2015, From 12:30-2:15 p.m. in Late-Breaking Abstract Session on Respiratory Physiology

NORWOOD, MA -- (Marketwired) -- 04/01/15 -- Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), a clinical stage drug development company focused on the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that positive pre-clinical data on the anti-fibrotic effects of Resunab™ will be presented today at the Experimental Biology 2015 scientific conference.

Abstract number LB744 entitled, "Anti-Fibrotic Effect of Ajulemic Acid in Bleomycin-Induced Lung Fibrosis," will be presented during today's Late-Breaking Abstracts poster session focused on respiratory physiology from 12:30-2:15 p.m. EDT in Hall B at the Boston Convention & Exhibition Center in Boston, Massachusetts. The Abstract will be presented by Monica Lucattelli, Ph.D., Researcher at the University of Siena, Siena, Italy.

Resunab, a proprietary ultrapure version of ajulemic acid with CB2 selectivity, is a novel synthetic oral drug with unique activity that resolves inflammation and progressive fibrosis. The data from the study conducted in animals with lung fibrosis induced by bleomycin demonstrated that oral treatment with Resunab at dose levels comparable to those safely administered to human subjects in Phase I trials significantly decreased fibrotic responses.

Additionally, there was a marked decrease by Resunab of TGF-β and CTGF expression, a significant reduction of α-SMA positive myofibroblasts and a significant increase of PPAR-γ expression observed in the Resunab treated animals. The study also concluded that Resunab exerted potent anti-fibrotic effects in bleomycin-induced lung fibrosis when administered at the initiation and during the ongoing fibrogenic phase.

"This animal study in this well validated model of pulmonary fibrosis adds to our growing body of data and provides additional pre-clinical confirmation of Resunab's potency in resolving inflammation and fibrosis," said Mark A. Tepper, Ph.D., President and Chief Scientific Officer of Corbus Pharmaceuticals. "The fact that anti-fibrotic effects were observed during early and later development stage of fibrosis in this model serves to validate Resunab's potential for the treatment of ongoing fibrotic diseases."

The abstract has been published online in The FASEB Journal, The Journal of the Federation of American Societies for Experimental Biology, (April 2015 vol. 29:LB744, no. 1 Supplement).

This study was conducted by Corbus Pharmaceuticals' collaborators M. Lucattelli, E. Selvi and G. Lungarella at the Life Sciences University of Siena, Italy; S. Fineschi, E. Garcia Gonzales, E. Balistrieri, S. Lorenzini, and M. Galeazzi at the Medicine and Immunological Sciences University of Siena, Siena Italy; and J.H.W. Distler at the Internal Medicine University of Erlangen-Nuremberg, Erlangen Germany.

About Resunab™
Resunab™ is a novel synthetic oral drug with unique activity that resolves inflammation and pro-fibrotic processes. Pre-clinical and Phase 1 clinical studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor on immune cells and triggers resolution of inflammation and a reduction of pro-inflammatory pathways, in effect turning chronic inflammation "off," without causing immunosuppression.

About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. Our lead product candidate Resunab™ is a novel oral drug that resolves chronic inflammation and pro-fibrotic processes. Resunab is scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse cutaneous systemic sclerosis (scleroderma) in 2015. For more information, please visit www.CorbusPharma.com.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact
Jenene Thomas
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: Email Contact

Source: Corbus Pharmaceuticals Holdings, Inc.

Released April 1, 2015